Investing.com - Financial Markets Worldwide
Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Valeant rejected joint takeover bid from Takeda, TPG in spring-WSJ

Published 2016-05-26, 07:59 p/m
© Reuters. Valeant rejected joint takeover bid from Takeda, TPG in spring-WSJ
BHC
-
4502
-

May 26 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX)
VRX.TO received a joint takeover offer from Japan's Takeda
Pharmaceutical Co Ltd 4502.T and TPG Capital Management LP
TPG.UL this spring that the Canadian drugmaker rejected, the
Wall Street Journal reported, citing people familiar with the
matter.
Valeant rejected the offer, which came a month or two ago,
before the company hired its new chief executive, Joseph Papa,
in April, and did not include a firm price, the newspaper
reported. (http://on.wsj.com/1TZplmC)
The newspaper also said there are currently no talks between
the three companies following the bid's rejection, and that
Valeant's board was seeking to give Papa time to chart a course
for the company.
Valeant's shares were up 5 percent at $28.45 on the New York
Stock Exchange in extended trading on Thursday.
TPG declined to comment. Takeda and Valeant did not
immediately respond to a request for comment.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.